No Data
No Data
No Data
No Data
No Data
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulp
BenzingaApr 30 08:06 ET
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
MT NewswiresApr 15 15:59 ET
Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise
Eagle Pharmaceuticals (EGRX) shares climbed 9% in recent trading after the company said Monday that it will present phase III trial data showing that intravenous amisulpride may sustain an antiemetic
MT NewswiresApr 15 13:49 ET
Express News | Eagle Pharmaceuticals To Present Additional Data From Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference
Moomoo 24/7Apr 15 07:25 ET
HROW, HCAT and EGRX Are Among After Hour Movers
Seeking AlphaApr 12 17:05 ET
Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays
TipRanksApr 12 16:34 ET
No Data
No Data